We use cookies to provide you with the best of services and customized features. By continuing to browse this website, you give your informed consent to our Cookie Policy.
A preclinical biotechnology company developing a disease-agnostic approach to overcome barriers to central nervous system treatments has garnered attention from New Ventures BC.
